VirtualScopics Inc

VirtualScopics — Shareholder Meeting (May 2009)

46 slides from VirtualScopics's shareholder meeting presentation, May 28, 2009

  1. Slide 1: Annual Stockholders' Meeting

    Annual Stockholders’ Meeting May 28, 2009

  2. Slide 2: Agenda

    Introductions and Opening Remarks Robert Klimasewski, Chairman Proxy Summons Robert Klimasewski Molly Henderson, Chief Business and Financial Officer Adjourn Business Overview Jeff Markin, Chief Executive Officer Molly Henderson Q & A Jeff Markin & Molly Henderson Proxy Tally and Results Robert Klim

  3. Slide 3: Agenda

    Introductions and Opening Remarks Robert Klimasewski, Chairman Proxy Summons Robert Klimasewski Molly Henderson, Chief Business and Financial Officer Adjourn Business Overview Jeff Markin, Chief Executive Officer Molly Henderson Q & A Jeff Markin & Molly Henderson Proxy Tally and Results Robert Klim

  4. Slide 4: Proxy Summons: Proposals

    Proposal 1 Election of Robert Klimasewski, Charles Phelps, Norman Mintz, Terence Walts, Jeff Markin, Mostafa Analoui, Dan Kerpelman, & Sidney Knafel to the Board of Directors Proposal 2 To approve an amendment to our Certificate of Incorporation, if necessary, to effect a reverse stock split of our

  5. Slide 5: Agenda

    Introductions and Opening Remarks Robert Klimasewski, Chairman Proxy Summons Robert Klimasewski Molly Henderson, Chief Business and Financial Officer Adjourn Business Overview Jeff Markin, Chief Executive Officer Molly Henderson Q & A Jeff Markin & Molly Henderson Proxy Tally and Results Robert Klim

  6. Slide 6: Agenda

    Introductions and Opening Remarks Robert Klimasewski, Chairman Proxy Summons Robert Klimasewski Molly Henderson, Chief Business and Financial Officer Adjourn Business Overview Jeff Markin, Chief Executive Officer Molly Henderson Q & A Jeff Markin & Molly Henderson Proxy Tally and Results Robert Klim

  7. Slide 7: Safe Harbor

    Safe Harbor This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance, or achie

  8. Slide 8: Presentation Overview

    Presentation Overview Company Overview Recap of 2008 objectives and performance Financial summary Personalized medicine (diagnostic) market assessment Question and answer session

  9. Slide 9: Key Company Highlights

    Key Company Highlights Integrated solution delivered as a series of services that manage imaging trials from inception to FDA submission. Highly automated quantitative analysis vs. conventional qualitative radiologist driven analysis. Very precise measurements that allow for trials to proceed with a

  10. Slide 10: Therapeutic Areas

    Therapeutic Areas Osteoarthritis Oncology Muscle Wasting Cardiovascular Central Nervous System Rheumatoid Arthritis Vascular Perfusion (DCE-MRI, DCE-CT) Tumor Volume Tumor Metabolism (FDG-PET) Cell Proliferation (FLT-PET) RECIST/WHO (Solid Tumor) Cheson (Lymphoma) Macdonald (Glioma) Muscle Volume fo

  11. Slide 11: Specific Example - Oncology

    Specific Example - Oncology Estimated 1.6 million new cases were diagnosed in 2008 NIH estimated the cost of cancer in 2008 to be $250 billion Mortality rates have declined over the past several years due to improved and targeted therapies Estimated market for imaging related clinical trial services

  12. Slide 12: Structural Imaging in Oncology

    Structural Imaging in Oncology Conventional Method -Traditional CT Image Crude 2D line used to characterize 3D object New therapies work from inside the tumor so overall length may not change Additional measures required to characterize response and progression of the disease

  13. Slide 13: Structural Imaging in Oncology

    Structural Imaging in Oncology VirtualScopics Patented Image & Data Analysis 3D measures required to characterize 3D objects New therapies require new techniques Industry is demanding high precision and sensitivity to change

  14. Slide 14: Structural Imaging in Oncology

    Structural Imaging in Oncology 3D Measure New Measure Old measure computed automatically Custom analysis designed specifically for the disease Quantitative and precise Opportunity to verify the mechanism of action of the compound

  15. Slide 15: Customer Value

    Customer Value Reduced number of subjects Higher precision = fewer patients Fewer patients = lower trial costs Accelerated time to market Smaller trial sizes = quicker enrollment and faster results Algorithm driven analysis yields results faster than radiologists driven analysis Better information f

  16. Slide 16: 2008 Focus

    2008 Focus ( Slide from 2008 Annual Meeting held in NYC on 5/8/2008) Operational Scale Efficiency Repeatability Customer service/focus New Customer Agreements Replicable projects Current and expanded customer base Achievement of financial targets Revenue growth Operating cash flow breakeven Progress

  17. Slide 17: Operational Scale

    Operational Scale Ability to process and deliver to clients greater volumes of work while delivering increasing levels of efficiency Gross profit margin = 50% delivered in Q4 2008 and Q1 2009 While meeting or exceeding customer requirements On-time delivery at 92% Global reach increasing Continuous

  18. Slide 18: Imaging Site Locations and European Office

    Imaging Site Locations and European Office South America North America EMEA (Europe, Middle East, & Africa) Asia Pacific UK Netherlands Spain Poland Hungary Romania Russia Egypt Finland Ireland Italy France Belgium Israel Serbia Austria Sweden Denmark Germany South Africa Croatia Slovakia VirtualSco

  19. Slide 19: Continuous Improvement Cycle

    Continuous Improvement Cycle 1. Plan Determine goals and changes necessary to achieve them 3. Check Evaluate the results in terms of performance 2. Do Implement the changes 4. Act a. If it worked, institutionalize/ standardize the change b. If not on target, implement countermeasures c. Continue the

  20. Slide 20: Continuous Improvement Methodology - Lean Six Sigma

    Continuous Improvement Methodology - Lean Six Sigma Uses time and the “relentless pursuit of waste elimination” as competitive leverages Seeks to make value flow throughout the entire process Using least amount of resources (time, people, materials, machines, energy, space) Creates a culture of neve

  21. Slide 21: New Customer Agreements

    New Customer Agreements Overall penetration of the industry as measured by: Active projects up 46% in 2009 vs. 2008 Late phase (Phase II and III) dollar value of projects represent ~55% vs. 27% in 2008 Dollar balance of awarded and signed contracts – project backlog is up 120% vs. 2008 Amount of pro

  22. Slide 22: 2008 Focus

    2008 Focus ( Slide from 2008 Annual Meeting held in NYC on 5/8/2008) Operational Scale Efficiency Repeatability Customer service/focus New Customer Agreements Replicable projects Current and expanded customer base Achievement of financial targets Revenue growth Operating cash flow breakeven Progress

  23. Slide 23: 2008 Financial Results

    2008 Financial Results Guidance Actual Revenues $7 million $7.1 million Q4 gross margin 50% 50% Q4 operating cash flow Breakeven Breakeven Achievement of all financial targets in 2008 26% revenue growth over prior year 58% increase in yearly gross profit 40% reduction in operating loss $1.5 million

  24. Slide 24: Revenues & Gross Profit – Quarterly

    Revenues & Gross Profit – Quarterly Trends Steady quarterly increase in revenues and gross profit Over the past 6 quarters – 50% increase in revenues, 120% increase in gross profit 90 active projects representing over 30 customers

  25. Slide 25: Operating Cash Flow – Quarterly Trend

    Operating Cash Flow – Quarterly Trend Greater than $600,000 reduction in quarterly cash outflow over the past 6 quarters Q1 2009, first quarter in history to generate cash from operations

  26. Slide 26: Project Balance (Backlog)

    Project Balance (Backlog) April 2009 – Project balance is $31,200,000, 120% increase over prior year Total backlog increased 67% in 2008, 10x increase in 4 years

  27. Slide 27: Years of Progress – A Tale of Two Companies

    4 Years of Progress – A Tale of Two Companies Today Revenues $2.5 million/year $2 million/quarter Customers Projects under management 35 (26 through Pfizer) 90+ Largest customer % 83% 17% Backlog $3,000,000 $31,000,000 FDA compliant environment (1-10 scale) 8.5 Employees Corporate structure Private

  28. Slide 28: Personalized Medicine (Diagnostic) Market Assessment

    Personalized Medicine (Diagnostic) Market Assessment

  29. Slide 29: Personalized Medicine Overview

    Personalized Medicine Overview Product/Service offering Overview of market need/opportunity Limitations in current standard of care Value proposition/Customer profile Competitive advantage Market size Regulatory requirements Insurance/Payer reimbursement Next steps

  30. Slide 30: Description of Product/Service

    Description of Product/Service

  31. Slide 31: Market Research

    Market Research Recent focus group discussions with: Radiologists 3 Oncologist groups Excellus (Blue Cross) Regulatory consultants Reimbursement consultants Online research into various aspects of the market

  32. Slide 32: Overview of Market Need/Opportunity

    Overview of Market Need/Opportunity Anti-angiogenic (AA) compounds Prevent growth of new blood vessels that fuel the growth of tumors Most often used in conjunction with chemotherapy 8 AA compounds approved/on the market today Commonly known compounds include: Avastin (Genentech), Sutent (Pfizer), H

  33. Slide 33: Overview of Market Opportunity (cont.)

    Overview of Market Opportunity (cont.) U.S. National Cancer Institute estimates: More than $4 billion has been invested in R&D for angiogenesis- based medicines Making this one of the most heavily funded areas of cancer research Estimated 14 million cancer patients could benefit from AA drugs Approv

  34. Slide 34: Value Proposition/Customer Profile

    Value Proposition/Customer Profile Customer groups benefiting from service Oncologists Patients Payer groups (HMOs, Medicare, etc.) Pharmaceutical companies Imaging equipment manufactures

  35. Slide 35: Competitive Advantage

    Competitive Advantage DCE-MRI procedures to assess blood flow have been used for many years – Unreliably VS offers highly reproducible and reliable measurements Can be used consistently across equipment manufacturers and imaging sites Patented and patent-pending algorithms and systems underlying the

  36. Slide 36: Market Size

    Market Size U.S. market opportunity today Based on the indications of cancer that AAs are currently approved, our estimate of the market is $460 million Variables included in estimate New incidences of disease in 2008 Price point used equals our current pricing for service Global market opportunity

  37. Slide 37: Regulatory Aspects

    Regulatory Aspects FDA approval requirements Medical device requirements Class I, Class II, and Class III designations Class II – 510k Requires predicate device for claims and to prove effectiveness and safety Class III – Pre-Market Approval (PMA) Necessary if no predicate device is available Requir

  38. Slide 38: Insurance/Payer Reimbursement

    Insurance/Payer Reimbursement Payer reimbursement (HMO, Medicare, etc.) Self pay market limited CPT code typically required for reimbursement by Payers Payer technology groups assess new technologies for possible reimbursement Includes feedback from impacted parties (Oncologists, Radiologists, etc.)

  39. Slide 39: Next Steps

    Next Steps Two phased approach Phase I Hire regulatory consultant to assist with FDA approval process Assist in the identification of predicate devices Collection of data to demonstrate effectiveness and benefit Complete and compile documentation regarding pre-production design controls of software

  40. Slide 40: Next Steps (cont.)

    Next Steps (cont.) Phase II: Heavily reliant on results of Phase I Collection of data to support strong correlation of response rates, if necessary As determined based on results of Phase I Develop go to market strategy Explore partnership opportunities Operational preparedness Financial requirement

  41. Slide 41: 2008 Focus

    2008 Focus ( Slide from 2008 Annual Meeting held in NYC on 5/8/2008) Operational Scale Efficiency Repeatability Customer service/focus New Customer Agreements Replicable projects Current and expanded customer base Achievement of financial targets Solid financial performance in 2008 26% increase in r

  42. Slide 42: Stock Price Performance

    Stock Price Performance – 6 months 130% increase in stock price since January 1, 2009 65% increase in daily trading volume

  43. Slide 43: 2009 Objectives

    2009 Objectives Early indicators in 2009 31% growth in 1 st quarter revenues 85% reduction in operating loss Operating cash flow generating Full year guidance Over 25% revenue growth anticipated ($9MM-$10MM) Gross margins = 50% Cash flow generating from operations Operations Continue to proactively

  44. Slide 44: Agenda

    Introductions and Opening Remarks Robert Klimasewski, Chairman Proxy Summons Robert Klimasewski Molly Henderson, Chief Business and Financial Officer Adjourn Business Overview Jeff Markin, Chief Executive Officer Molly Henderson Q & A Jeff Markin & Molly Henderson Proxy Tally and Results Robert Klim

  45. Slide 45: Agenda

    Introductions and Opening Remarks Robert Klimasewski, Chairman Proxy Summons Robert Klimasewski Molly Henderson, Chief Business and Financial Officer Adjourn Business Overview Jeff Markin, Chief Executive Officer Molly Henderson Q & A Jeff Markin & Molly Henderson Proxy Tally and Results Robert Klim

  46. Slide 46: Agenda

    Introductions and Opening Remarks Robert Klimasewski, Chairman Proxy Summons Robert Klimasewski Molly Henderson, Chief Business and Financial Officer Adjourn Business Overview Jeff Markin, Chief Executive Officer Molly Henderson Q & A Jeff Markin & Molly Henderson Proxy Tally and Results Robert Klim

VirtualScopics — Shareholder Meeting (May 2009) on 6ix